Latest news with #BioconLimited
Business Upturn
4 days ago
- Business
- Business Upturn
Biocon receives CDSCO approval for its Liraglutide drug in India
Biocon Limited, a global biopharmaceutical company, has announced that it has received regulatory approval in India for its Liraglutide drug substance. Its wholly owned subsidiary, Biocon Pharma Limited, has also secured approval for the Liraglutide drug product (6 mg/ml solution for injection in pre-filled pen and cartridge) from the Central Drugs Standard Control Organisation (CDSCO). The product is a generic version of Victoza®, used as an adjunct to diet and exercise to improve glycemic control in adults, adolescents, and children aged 10 years and older with Type 2 Diabetes Mellitus that is not adequately managed. Siddharth Mittal, Chief Executive Officer and Managing Director, Biocon Ltd, commented, 'The approval of our first vertically integrated GLP-1 in India, Liraglutide, is another significant step forward in expanding access of this product to patients suffering from diabetes. India has one of the highest number of people with diabetes globally, with estimates exceeding 77 million cases, and expected to rise further. The approval enables us to address a critical need by making this drug available, and aligns with Biocon's mission to provide affordable, lifesaving medications to those who need it the most. We are now gearing up to launch the product expeditiously through our commercialization partners in India'' This approval was granted under the CDSCO's recently introduced 101 route. This regulatory pathway allows for the recognition of approvals issued by referenced and established foreign regulatory agencies, thereby facilitating faster access to critical medicines in India. Glucagon-like peptide-1 (GLP-1) therapies, including Liraglutide, are being recognized as a growing segment in diabetes management. Biocon has stated its intent to expand its portfolio in this category as part of its future business strategy. Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
Mint
28-05-2025
- Business
- Mint
Bengaluru's Kiran Mazumdar-Shaw opts for metro travel over luxury car, accompanied by ‘Namma Metro friend'
Bengaluru billionaire Kiran Mazumdar-Shaw ditched her luxury vehicles for a ride on the city's metro this Tuesday, opting to travel via the Namma Metro purple line to escape Bengaluru's notorious traffic congestion. Sharing her experience on the social media platform X, the Biocon Limited founder expressed surprise at the efficiency of the metro journey and praised the Bangalore Metro Rail Corporation for providing a 'great ride.' Shaw was accompanied by her friend Jennifer Erich, whom she referred to as the 'Iron Lady at Exxon Mobil.' Erich, according to her LinkedIn profile, holds the position of Geoscience Manager at Exxon Mobil's Bengaluru Technology Centre. 'Took the purple line from Whitefield to Vidhana with my Namma Metro friend Jennifer Erich, the Iron Lady of Exxon Mobil. Such a quick way to avoid traffic. Great ride. Thanks BMRCL,' Mazumdar-Shaw wrote on X. Jennifer Erich responded to the post by saying she was happy to have introduced Namma Metro to Shaw. 'So happy to be your Metro Mentor!! Thanks so much for joining me at my office today,' she replied. Online audiences expressed strong appreciation for Kiran Mazumdar-Shaw's humble and relatable gesture. 'Great to see famous personalities doing this and sharing - very important to have more people take public transport,' wrote one person. 'When the affluent, influential, and elite embrace public transport, it catalyzes systemic investment and inspires emulation among the masses, dismantling car-centric aspirations and heralding a shift toward sustainable urban mobility,' another said. What is Namma Metro? Namma Metro, commonly referred to as Bengaluru Metro, is the rapid transit network serving Bengaluru, the capital of Karnataka. The system is managed by the Bangalore Metro Rail Corporation Limited (BMRCL), a partnership between the Government of India and the Government of Karnataka. Currently, Namma Metro operates two lines: the purple line and the green line. Kiran Mazumdar-Shaw is not the first billionaire to opt for public transport. In 2023, real estate tycoon Niranjan Hiranandani took a Mumbai local train to 'save time and beat the traffic.'
United News of India
02-05-2025
- Business
- United News of India
Biocon to invest in Maharashtra, we will support: CM Fadnavis
West Mumbai, May 2 (UNI) India's largest bio-phrmaceutical company Biocon Limited is keen to invest in Maharashtra through a drug manufacturing project, Chief Minister Devendra Fadnavis announced on Friday. promising to provide necessary support for the endeavour. Fadnavis was speaking during a meeting with the Executive Chairman of Biocon Limited, Kiran Shaw Muzumdar, at the 'Waves 2025 Audiovisual Entertainment Summit' here. Fadnavis said state government officials will have preliminary discussions with the Biocon Management Committee in this regard. He said the state government will provide all possible support to Biocon to invest in Maharashtra. Biocon, which will soon become the world's leading company in insulin production, wants to start a production unit in Pune area, said Kiran Majumdar Shaw. UNI VKB SSP Tags: #Biocon to invest in Maharashtra # we will support: CM Fadnavis
Hans India
28-04-2025
- Politics
- Hans India
Kiran Mazumdar Shaw Calls Bengaluru a 'Garbage City,' Check Her Post Here
Kiran Mazumdar-Shaw, Executive Chairperson of Biocon Limited, criticized Bengaluru's condition, stating that the city is becoming a "garbage city" instead of the once-planned Garden City. She shared a video from Lal Bagh and called on citizens to take action and restore the city. Her comments followed BJP MP Tejasvi Surya's letter to Bengaluru Incharge Minister DK Shivakumar and BBMP Commissioner Tushar Girinath. Surya pointed out the poor state of roads and public infrastructure during the TCS World 10K race, mentioning potholes, garbage, and broken footpaths, which he said created a negative image of the city.
Business Upturn
23-04-2025
- Business
- Business Upturn
Biocon to raise Rs 4,500 crore via QIP or other routes
Biocon Limited has announced that its board of directors has approved a proposal to raise up to ₹4,500 crore through a mix of instruments, including equity shares, convertible securities, non-convertible debt instruments with warrants, or other eligible options. The fundraising will be executed via qualified institutions placements (QIP), rights issues, preferential allotments, private placements, or a combination thereof, subject to shareholder and regulatory approvals. Additionally, the board approved an increase in the authorised share capital of the company from ₹625 crore to ₹700 crore. The capital restructuring will result in the authorised capital being divided into 140 crore equity shares of ₹5 each, up from the existing 125 crore shares. A corresponding amendment to the Memorandum of Association of the company will follow, pending approvals. The company will seek shareholders' approval for both resolutions via postal ballot, details of which will be communicated shortly. The decision marks a significant step in Biocon's growth strategy and comes as the company looks to strengthen its balance sheet, fund expansion, and potentially explore strategic opportunities across its biosimilars, generics, and research services businesses. Disclaimer: This news article is based on public disclosures made to stock exchanges. Investors are advised to consult certified financial advisors before making investment decisions. News desk at
